Winning Health Technology Group (300253) Fair Value & Analysis
Healthcare · CN · Market cap 15.9B CNY
Analysis
Winning Health Technology Group (300253) currently trades at ¥7.33, while our model-based Fair Value estimate is ¥2.08 — implying the stock looks roughly 71.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Winning Health Technology Group Co., Ltd., together with its subsidiaries, provides digital health services for medical and health institutions in China. The company offers WiNEX, a digital health platform; internet and health care; smart hospital; smart regional healthcare; and WinCloud solutions. Its solutions are used in smart hospitals, regional health, public health, medical insurance, health services, and other fields. The company is involved in general items; software development; information system operation and maintenance; investment; non-residential real estate leasing; technology development, transfer, and promotion; and medical device sale. In addition, it provides computer hardware, software, and peripherals; information technology consulting; internet data; technical consulting; and technical services. The company was formerly known as Shanghai Kingstar Winning Software Co., Ltd. and changed its name to Winning Health Technology Group Co., Ltd. in January 2016. Winnin…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.